Neumora Therapeutics, Net Worth
Neumora Therapeutics, Net Worth Breakdown | NMRA |
Neumora Therapeutics, Net Worth Analysis
Neumora Therapeutics,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Neumora Therapeutics,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Neumora Therapeutics,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Neumora Therapeutics,'s net worth analysis. One common approach is to calculate Neumora Therapeutics,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Neumora Therapeutics,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Neumora Therapeutics,'s net worth. This approach calculates the present value of Neumora Therapeutics,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Neumora Therapeutics,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Neumora Therapeutics,'s net worth. This involves comparing Neumora Therapeutics,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Neumora Therapeutics,'s net worth relative to its peers.
To determine if Neumora Therapeutics, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neumora Therapeutics,'s net worth research are outlined below:
| Neumora Therapeutics, generated a negative expected return over the last 90 days | |
| Neumora Therapeutics, has high historical volatility and very poor performance | |
| Neumora Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (235.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neumora Therapeutics, generates negative cash flow from operations | |
| Neumora Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| About 64.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Neumora Therapeutics, Inc. This Small-Cap Stock Is Ready To Explode |
Neumora Therapeutics, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neumora Therapeutics, Common. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neumora Therapeutics,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Neumora Therapeutics,'s market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.61 B.Market Cap |
|
Project Neumora Therapeutics,'s profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.48) | (0.50) | |
| Return On Equity | (0.50) | (0.48) |
When accessing Neumora Therapeutics,'s net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Neumora Therapeutics,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neumora Therapeutics,'s profitability and make more informed investment decisions.
Please note, the presentation of Neumora Therapeutics,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neumora Therapeutics,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neumora Therapeutics,'s management manipulating its earnings.
Evaluate Neumora Therapeutics,'s management efficiency
Neumora Therapeutics, has return on total asset (ROA) of (0.3775) % which means that it has lost $0.3775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7708) %, meaning that it created substantial loss on money invested by shareholders. Neumora Therapeutics,'s management efficiency ratios could be used to measure how well Neumora Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. As of December 3, 2024, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.42. The current year's Other Assets is expected to grow to about 5.1 M, whereas Total Assets are forecasted to decline to about 340.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.95 | 3.10 | |
| Tangible Book Value Per Share | 2.95 | 3.10 | |
| Enterprise Value Over EBITDA | (12.47) | (13.10) | |
| Price Book Value Ratio | 5.77 | 6.06 | |
| Enterprise Value Multiple | (12.47) | (13.10) | |
| Price Fair Value | 5.77 | 6.06 |
The strategic initiatives led by Neumora Therapeutics,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Equity (0.77) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neumora Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neumora Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neumora Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neumora Therapeutics, Corporate Filings
F3 | 22nd of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 18th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
ASR | 1st of October 2024 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Neumora Therapeutics, Earnings per Share Projection vs Actual
Neumora Therapeutics, Corporate Management
| Jason JD | Chief Officer | Profile | |
| Nicholas Brandon | Chief Officer | Profile | |
| Amy Sullivan | Senior Resources | Profile | |
| John Reynders | Chief Advisor | Profile | |
| Michael Milligan | Principal Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neumora Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Return On Assets (0.38) | Return On Equity (0.77) |
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.